PHEXXI Drug Patent Profile

Which patents cover Phexxi, and when can generic versions of Phexxi launch?

Phexxi is a drug marketed by Evofem Inc and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has forty-six patent family members in eighteen countries.

The generic ingredient in PHEXXI is citric acid; lactic acid; potassium bitartrate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the citric acid; lactic acid; potassium bitartrate profile page.

DrugPatentWatch^® Generic Entry Outlook for Phexxi

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 15, 2033. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for PHEXXI

International Patents:	46
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	3
Drug Prices:	Drug price information for PHEXXI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PHEXXI
What excipients (inactive ingredients) are in PHEXXI?	PHEXXI excipients list
DailyMed Link:	PHEXXI at DailyMed

See drug prices for PHEXXI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for PHEXXI

NDA:

208352

Dosage:

GEL;VAGINAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for PHEXXI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Queen's Medical Center	Early Phase 1
University of Hawaii Foundation	Early Phase 1
Parexel	Phase 3

See all PHEXXI clinical trials

Pharmacology for PHEXXI

Drug Class	Anti-coagulant Calculi Dissolution Agent
Mechanism of Action	Acidifying Activity Calcium Chelating Activity
Physiological Effect	Decreased Coagulation Factor Activity

Paragraph IV (Patent) Challenges for PHEXXI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PHEXXI	Vaginal Gel	citric acid; lactic acid; potassium bitartrate	1.8%/1%/0.4%	208352	1	2023-02-28

US Patents and Regulatory Information for PHEXXI

PHEXXI is protected by four US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Evofem Inc	PHEXXI	citric acid; lactic acid; potassium bitartrate	GEL;VAGINAL	208352-001	May 22, 2020		RX	Yes	Yes
Evofem Inc	PHEXXI	citric acid; lactic acid; potassium bitartrate	GEL;VAGINAL	208352-001	May 22, 2020		RX	Yes	Yes			Y	Y
Evofem Inc	PHEXXI	citric acid; lactic acid; potassium bitartrate	GEL;VAGINAL	208352-001	May 22, 2020		RX	Yes	Yes
Evofem Inc	PHEXXI	citric acid; lactic acid; potassium bitartrate	GEL;VAGINAL	208352-001	May 22, 2020		RX	Yes	Yes

Expired US Patents for PHEXXI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Evofem Inc	PHEXXI	citric acid; lactic acid; potassium bitartrate	GEL;VAGINAL	208352-001	May 22, 2020

International Patents for PHEXXI

When does loss-of-exclusivity occur for PHEXXI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

China

Denmark

European Patent Office

Israel

Japan

Mexico

New Zealand

Russian Federation

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering PHEXXI around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	60143566
Mexico	2016008023	COMPOSICIONES Y METODOS PARA INHIBIR LA INFLAMACION Y LAS ENFERMEDADES UTILIZANDO UN COMPUESTO ANTIMICROBIANO CON BASE EN ACIDO ALGINICO. (COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND.)
Mexico	2019007176	COMPOSICIONES Y METODOS PARA MEJORAR LA EFICACIA DE MICROBICIDAS ANTICONCEPTIVOS. (COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES.)
Japan	2018109034	避妊殺菌剤の効果を増強するための組成物および方法 (COMPOSITIONS AND METHODS FOR ENHANCING EFFICACY OF CONTRACEPTIVE MICROBICIDES)
Poland	365461

Market Dynamics and Financial Trajectory for PHEXXI

Last updated: January 5, 2026

Executive Summary

PHEXXI (acetowhite, citric acid, and nonoxynol-9) marks a significant shift in the contraceptive market as a women-controlled, hormone-free vaginal contraceptive approved by the FDA in 2020. This report analyzes PHEXXI’s market landscape, competitive positioning, revenue potential, and future growth trajectory. Key factors influencing its market dynamics include regulatory environment, consumer preferences for non-hormonal options, competitive landscape, reimbursement policies, and potential pipeline developments. The drug’s financial trajectory hinges on market acceptance, payer coverage, and demographic trends, with an estimated initial global market potential ranging from $300 million to $500 million annually over the next five years.

---

Market Overview: What is PHEXXI?

Product Description
PHEXXI is a non-hormonal, on-demand vaginal contraceptive approved by the U.S. Food and Drug Administration (FDA) in August 2020. It contains three active ingredients:

Active ingredients	Function	Indications
Acetowhite	pH modifier, acidifies vaginal pH	Contraceptive
Citric acid	Lowers vaginal pH	Contraceptive
Nonoxynol-9	Spermicidal agent	Contraceptive

Mechanism of Action
PHEXXI maintains the acidic vaginal environment (pH ~3.5–4.0), inhibiting sperm motility and viability, thereby preventing fertilization. It is applied prior to intercourse, offering a user-controlled, hormone-free alternative to systemic contraceptives.

Target Population
Women aged 18-45 seeking non-hormonal, on-demand contraception, particularly those with contraindications to hormonal methods or preferences for hormone-free options.

---

Market Dynamics: Key Drivers and Barriers

Drivers

Driver Factors	Description	Impact
Rising demand for hormone-free methods	Patients favor non-hormonal options due to side effect concerns or health risks	Increased market penetration
Convenience of on-demand application	Ease of use aligns with user preferences for discreet, on-demand contraception	Boosts adoption rates
Growing awareness of reproductive rights	Empowerment initiatives encourage women to choose self-controlled methods	Expands user base
Reimbursement and insurance coverage	Covering PHEXXI reduces out-of-pocket costs	Accelerates uptake
Competitive differentiation	Hormone-free, local-application, with a different side-effect profile	Differentiates from pills, IUDs

Barriers

Barrier Factors	Description	Impact
Limited familiarity and awareness	Low initial awareness among healthcare providers and consumers	Slows initial adoption
Higher cost compared to traditional methods	PHEXXI's retail price (€45-€60 per unit in the US)	May hinder accessibility
Reimbursement hurdles	Payer policies may delay coverage or restrict use	Constrains market expansion
Competition from established methods	Pills, IUDs, implants with larger market share	Limits market share growth
User willingness for on-demand use	Requires user compliance and consistent pre-coital application	Possible compliance issues

Regulatory and Policy Environment

The contraceptive market is heavily influenced by government policies, including:

• FDA approvals: As the sole regulatory body in the US, FDA approval (2020) permitted entry but did not ensure widespread acceptance.
• Reimbursement policies: Vary by insurer; inclusion in formularies affects sales.
• Global regulations: Approval status outside the US remains limited; expansion depends on local regulatory processes.

---

Competitive Landscape

Existing Competitors

Competitor	Product Type	Market Share	Key Differentiator
Oral contraceptive pills	Hormonal, daily regimen	~86% (US, 2022)	Well-established, high adherence
IUDs (e.g., Mirena)	Long-acting, hormonal/non-hormonal	~15%	Long-lasting, high efficacy
Condoms	Barrier method	Varies	Widely accessible, non-prescription
FemCap, diaphragm	Barrier devices	Niche	Reusable, user-controlled
OTC options (e.g., spermicide)	OTC, on-demand agents	Low market share	Historically less popular, less effective

PHEXXI’s Positioning
Unique for being hormone-free, on-demand, and women-controlled, targeting a niche underserved by traditional hormonal methods.

Future Competitors and Pipeline Products

Species	Expected Entry	Features	Status
Progestin-free vaginal rings	2025+	Extended efficacy, hormone-free	Clinical trials underway
New spermicides/formulations	2023-2025	Enhanced efficacy, reduced side effects	R&D investments increasing

---

Financial Trajectory: Revenue Projections and Market Share

Market Size Estimation

Year	US Market Potential	Global Market Potential
2023	$150 million	$300 million
2024	$200 million	$400 million
2025	$250 million	$500 million
2026	$300 million	$600 million
2027	$350 million	$700 million

Assumptions:

• 10-25% penetration in target demographics over five years.
• Average price per unit: $55 (US).
• Initial market share: 2% (2023), reaching 10% by 2027.

Revenue Breakdown

Parameter	Assumption	Net Revenue (annual) in US 2023	Notes
Units sold	3 million units (assuming 2% of women seeking contraception)	$165 million	Based on target population estimates
Reimbursement rate	70% covered by insurance	~$115.5 million	Adjusted for payer coverage fluctuations
Price per unit	$55	-	Approximate retail average

Growth Factors

Factor	Influence on Revenue Trajectory
Physician prescribing habits	Influences initial adoption rates
Payer coverage policies	Critical for adoption; positive policies accelerate growth
Awareness campaigns	Increase demand and market penetration
Competitive innovations	May dilute market share if competitors introduce better products

---

Comparison with Other Contraceptives

Contraceptive Method	Efficacy (Typical Use)	Duration of Effect	User Control	Hormonal Content	Cost (US)	Reimbursement Likelihood
Oral pills	91%	Daily	Yes	Yes	$20/month	High
Copper IUD	>99%	10+ years	No	No	$500–$1,000*	Moderate to high
PHEXXI	86% (approximate)	Pre-coital, on-demand	Yes	No	$55/unit	Increasing with policy
Condom	85%	Per act	Yes	No	$1–$3 per condom	High, OTC

*Note: Cost varies by insurer coverage.

---

Regulatory and Policy Considerations

• FDA Status: Approved August 2020, but subsequent market acceptance depends on provider and payer education.
• Reimbursement Policies: Currently limited but expected to expand as awareness and evidence grow.
• Global Expansion: Approval in Europe and Asia varies; regulatory pathways are complex, but potential markets include Europe, Canada, Australia, and parts of Asia.

---

Market Outlook and Growth Opportunities

Short-Term Opportunities (2023-2025)

• Raise awareness among healthcare providers and consumers.
• Secure payer inclusion and reimbursement.
• Strategize marketing targeted at contraceptive users seeking hormone-free options.
• Expand distribution channels and pharmacy placements.

Long-Term Opportunities (2025+)

• Development of extended-release formulations or combination products.
• Entry into international markets contingent on local approvals.
• Innovation in delivery mechanisms (e.g., sustained-release rings).
• Integration into contraceptive guidelines and health policy frameworks.

---

Deep-Dive: Key Challenges and Risks

Risk Category	Description	Mitigation Strategies
Regulatory Hurdles	Additional approvals needed for global expansion	Early engagement with regulators
Market Acceptance	Slow uptake due to lack of awareness or entrenched preferences	Educational campaigns, physician advocacy
Competitive Innovations	Future products with superior efficacy or convenience	Continuous R&D, patent protections
Pricing and Reimbursement	Out-of-pocket costs affecting access	Price negotiations, formulary inclusion
Supply Chain Disruptions	Manufacturing or distribution disturbances	Diversified manufacturing sources

---

Key Takeaways

• Market Opportunity: PHEXXI addresses a growing demand for non-hormonal, user-controlled contraception, with an initial US market potential of approximately $150–$200 million annually.
• Growth Drivers: Rising consumer preference for hormone-free options, reimbursement policies, and increased awareness bolster market growth.
• Challenges: Competition from entrenched methods, limited initial awareness, and reimbursement hurdles pose barriers.
• Financial Trajectory: Revenue may reach $250 million annually in the US by 2025, expanding globally contingent on regulatory and market factors.
• Strategic Consideration: Prioritizing payer coverage, physician education, and consumer awareness are critical for optimizing returns.

---

FAQs About PHEXXI

Q1: What are the primary advantages of PHEXXI over traditional hormonal contraceptives?
PHEXXI is hormone-free, can be applied on-demand before intercourse, and offers women greater control without systemic hormonal side effects.

Q2: How does PHEXXI compare in efficacy to other contraceptives?
With an efficacy rate of approximately 86% under typical use, PHEXXI is comparable to condoms and spermicides but less effective than intrauterine devices or pills.

Q3: What are the major barriers to PHEXXI’s market adoption?
Limited awareness, higher cost, reimbursement challenges, and competition from established hormonal methods are key barriers.

Q4: What is the current regulatory status of PHEXXI in markets outside the US?
As of early 2023, PHEXXI has FDA approval in the US, with filings underway or anticipated in Europe, Canada, and select Asian countries.

Q5: How might new innovations affect PHEXXI’s market share?
Emerging products like long-acting non-hormonal vaginal rings could compete with PHEXXI, emphasizing the need for continual R&D and differentiation.

---

References

[1] U.S. Food and Drug Administration. PHEXXI (acetic acid, citric acid, and nonoxynol-9) Vaginal Gel. August 2020.
[2] Guttmacher Institute. Contraceptive Use in the United States. 2022.
[3] MarketWatch. Female Contraceptive Market Size, Share & Trends. 2023.
[4] WHO. Contraceptive Options and Access. 2021.
[5] IQVIA. Global Contraceptive Market Analysis. 2022.

---

This comprehensive overview aims to inform healthcare professionals, investors, and industry stakeholders about PHEXXI’s current market position and future prospects, emphasizing strategic insights for decision-making.